Smartest Doc
Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
Journal of Cancer Research & Clinical Oncology, 07/05/2012
Zhu Y et al. – CS provides useful information regarding life expectancy for survivors of advanced RCC treated with targeted therapy. Furthermore, disease control status within a specific period of time is critical to the prediction of subsequent survival.
Methods- A total of 345 patients treated between 2006 and 2011 fulfilled the inclusion criteria and were reviewed for analyses.
- The 1-year conditional and actual survival rates were calculated for survivors from treatment to month 24. Subgroup-specific CS rates were generated after adjustment of the covariate influence.
- The Cox proportional hazard models were used to assess the prognostic factors at baseline and 1-year landmark.
- The probabilities of surviving an additional year given survival to 6, 12, 18, and 24 months were 72.2, 76.3, 78.2, and 78.6 %, respectively.
- Remarkable increase in CS was observed in patients initially classified as intermediate or poor risk according to Heng risk groups.
- For patients survived 24 months after treatment, the adjusted CS for the following year was over 80 % regardless of initial risk attribution.
- Compared to baseline analysis, Heng risk groups were less predictive of survivorship after surviving 1 year.
- The addition of disease control status to multifactorial model significantly improved survival estimation for 1-year survivors (p < 0.01).
